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Background: Aberrant microRNA (miRNA) expression plays an essential role in osteosarcoma (OS) pathogenesis.
Recent studies have shown that dysregulation of miRNA expression is associated with increased tumorigenesis
and poor prognosis in several types of cancers, including OS. The aim of this study was to investigate the relevant
microRNAs involved in the development of OS.
Methods: To explore possible oncogenic factors in OS, we used a microarray-based approach to profile changes in
the expression of miRNAs and their target mRNAs in five OS cell lines and human mesenchymal stem cells (hMSCs).
An miRNA, miR-93, was significantly up-regulated, whereas phosphatase and tensin homologue (PTEN) expression
was significantly down-regulated in all tested OS cells, when compared with hMSCs.
Results: When anti-miR-93 was transfected into OS cell lines, PTEN expression was greatly increased, suggesting
that PTEN might be a target of miR-93 in ES cells. The expression of phosphorylated Akt protein, which is known to
be inversely correlated with that of PTEN, was significantly down-regulated in anti-miR-93-transfected cells.
Furthermore, transfection of anti-miR-93 inhibited the proliferation and cell cycle progression of ES cells. In addition,
the down-regulation of miR-93 in these cells significantly suppressed tumor growth in vivo.
Conclusion: Ectopic expression of miR-93 decreased PTEN protein levels. Furthermore, miR-93 increased
proliferation and decreased apoptosis in OS cells, whereas its silencing in these cells inhibited such carcinogenic
processes. Taking these observations together, miR-93 can be seen to play a critical role in carcinogenesis through
suppression of PTEN, and may serve as a therapeutic target for the treatment of OS.Introduction
Osteosarcoma (OS) is the most common primary malig-
nant bone tumor in children and adolescents. Trad-
itional therapeutic approaches include local control of
the primary lesion by surgery and/or chemotherapy, and
treatment of disseminated disease with multiagent cyto-
toxic chemotherapy. However, over the last three de-
cades, there have been no noticeable improvements in
patient survival, especially for the subgroup having
shown metastasis at diagnosis [1, 2].
MicroRNAs (miRNAs) have been shown to be import-
ant post-transcriptional regulators of gene expression in
both cancer cells and normal cells. These noncoding
small RNAs bind to specific cognate sequences in the
3′-untranslated region (3′-UTR) of target transcripts,* Correspondence: ktanaka@oita-u.ac.jp
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creativecommons.org/publicdomain/zero/1.0/usually resulting in translational repression and gene
silencing [3, 4].
MiR-93 expression has been implicated in various
cancer types, implying an oncogenic role [5–7]. In
breast cancer, its overexpression has been correlated
with proliferation and tumor progression [8]. How-
ever, the role of miR-93 in the proliferation of OS
cells remains unclear.
Studies of phosphatase and tensin homologue (PTEN)
expression in a variety of malignancies including breast,
gastric, esophageal, and uterine cancers have demon-
strated that reduced PTEN levels are associated with
poor prognoses [9–13].
In the present study, we analyzed genome-wide ex-
pression arrays of both miRNAs and mRNAs in five hu-
man OS cell lines and human mesenchymal stem cells
(hMSCs). Our results indicated that the expression of
miR-93 was elevated while that of PTEN was repressed
in all five OS cell lines, in comparison to hMSCs. Basedarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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effect of PTEN in OS cells may be directly or indirectly
mediated, at least in part, via miR-93. The purpose of
our study was to assess whether the expression of PTEN
is repressed by miR-93 and to establish whether this
pathway could play a role in tumorigenesis in OS cells.
Material & methods
Cell lines
The human OS cell lines—HOS, SaOS, and MG-
63—were obtained from RIKEN Cell Bank (Tsukuba,
Japan), and NY and Hu09 were obtained from JCRB Cell
Bank (Osaka, Japan). hMSCs were purchased from
TaKaRa Biotechnology (Otsu, Japan). The genotype and
phenotype of each cell line was authenticated by the
respective source company. HOS cells were grown in
minimal essential medium (MEM) supplemented with
10 % fetal bovine serum (FBS; Invitrogen, NY) and
0.1 mmol/L nonessential amino acids (NEAA). SaOS,
MG-63, and NY cells were cultured in a high-glucose
medium, Dulbecco’s modified eagle medium (DMEM)
(Invitrogen, NY) supplemented with 10 % FBS and 1 %
penicillin and streptomycin. The Hu cells were cultured
in Roswell Park Memorial Institute medium (RPMI)
1640 (Invitrogen) supplemented with 10 % FBS. hMSCs
were cultured with the Chemically Defined Mesenchy-
mal Stem Cell Basal Medium (MSCBM-CD) with
MSCGM-CD SingleQuats (TaKaRa Biotechnology). The
cells were maintained at 37 °C under 5 % CO2, and pas-
saged every 2–3 days.
Ethics statement
The animal experimental protocol was approved by the
Ethics Review Committee for Animal Experimentation
of Oita University, and all mice used in this study were
anesthetized with ketamine/xylazine or isoflurane/oxy-
gen for experiments and euthanized with cervical
dislocation under anesthesia. All efforts were made to
minimize suffering.
Mice
BALB/c nu/nu mice, (n = 28, 6 week old,), were ac-
quired from the Kyodo Laboratory (Tosu, Japan).
After quarantine, all mice were kept in a pathogen
free environment on a standard 12 hr-day/12 hr-night
cycle and were fed a standard sterilized pellet diet
and water ad libitum. All mice were continuously
monitored during daytime from Monday to Friday,
and twice daily during daytime on Saturdays, Sundays,
and holidays for signs of poor health.
RNA isolation
mRNAs were prepared from the triplicated cell cultures
using RNeasy kit (Qiagen, Valencia CA) according to themanufacturer’s instruction. The RNA quality was en-
sured, before labeling, using RNA 6000 Nano kit and
Bioanalyzer 2100 (Agilent, Santa Clara, CA). miRNAs
were prepared from triplicate cell cultures using the
miRNeasy Mini kit (Qiagen) according to the manufac-
turer’s instruction.
Genome-wide miRNA expression microarray
GeneChip miRNA 3.0 array (Affymetrix, Santa Clara,
CA) was used for miRNA expression profiling in five OS
cell lines and hMSCs. One μg of small RNA including
miRNA from each sample was labeled with biotin using
the FlashTag Biotin HSR Kit (Genisphere, Hatfield, PA).
Array hybridization, washing and scanning of the slides
were carried out according to the manufacture’s recom-
mendations. The data were extracted from the images,
quantile-normalized, summarized (median polish), and
log2-transformed with miRNA QC software (Affymetrix).
GeneSpring GX 11.0 (Agilent) was used to analyze the
array results. Analysis of variance was used to determine
those probe sets significantly different between the two
groups. The gene list was filtered with a fold-change cutoff
of 2 resulting in the output of list with genes that have sig-
nificant differential expression at 2-fold or more differences.
Pathway analysis was performed using KEGG PATHWAY
Database (http://www.genome.jp/kegg/pathway.html).
Analysis of mRNA expression by cDNA arrays
GeneChip Genome HG U133 Plus 2.0 Array (Affyme-
trix) was used for mRNA expression profiling in five OS
cell lines and hMSC. Biotinylated cRNA was synthesized
from total RNA using the 3′ IVT Express Kit (Affyme-
trix) according to the manufacturer’s protocols. In brief,
double stranded cDNA was generated by reverse tran-
scription from 1 ng of total RNA an oligo (dT) primer
bearing a T7 promoter. The double-strand cDNA was
used as a template for in vitro transcription to generate
biotin-labeled cRNA. After fragmentation, 12.5 μg of
cRNA were hybridized to GeneChip array for 16 hr. The
arrays were washed and stained using GeneChip Fluidics
Station 450 (Affymetrix) and then scanned with the
GeneChip Scanner 3000 (Affymetrix). The entire experi-
ment was performed twice. Array hybridization, wash-
ing, and scanning of the slides were carried out
according to the manufacture’s protocols. The micro-
array numerical values were analyzed using the Gene-
Spring GX 11.0 software: quantile normalization, filter
by flags (detected), filter by expression on the normal-
ized data (20.0–100.0th percentile). Analysis of variance
was used to determine those probe sets significantly
different between the two groups. The gene list was
filtered with a fold-change cutoff of 2, resulting in out-
put of list with genes that have significant differential
expression at 2-fold or more differences.
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Basic Local Alignment Search Tool (BLAST), TargetScan
6.0, microRNA.org, was used to search for predicted the
target genes of miRNAs.
Prediction of binding site and mature miRNA transfection
Among the predicted target genes of miR-93 in the
TargetScan (http://www.targetscan.org/), DIANA (http://
diana.cslab.ece.ntua.gr/microT/), and PicTar (http://pic
tar.mdc-berlin.de/) databases, we found that PTEN was
one of the top candidates. One day prior to the transfec-
tion, cells were seeded onto 6 well plates (1 × 105 cells/
well) and incubated with the complete medium without
antibiotics (2 ml/well). Actinomycin D (10 μg/ml, Sigma-
Aldrich) was used to inhibit nascent RNA synthesis. The
transfection of miR-93-5p mimic (5′- CAAAGUGCUGU
UCGUGCAGGUAG-3′) (20nM), miR-93-5p mutant (5′-
CUUUCACGUGUUCGUGCAGGUAG-3′) (20nM) and
negative control (NC) mRNAs (20nM) (Invitrogen) was
performed using Lipofectamine 2000 reagent (Invitrogen)
in antibiotics-free OptiMEM (Invitrogen) according to the
manufacturer’s instructions. After 48 h incubation following
the transfection, the cells were harvested and processed for
further analysis.
RNA extraction, cDNA synthesis, and quantitative real
time PCR
Total RNA was extracted from treated cells with the
TRizol reagent (Invitrogen) and cDNA was synthesized
according to the manufacturer’s protocol (Roche).
Quantitative real-time PCR (qRT-PCR) was performed
using a Light Cycler 480 Probe Master System (Roche),
and PCR-specific amplification was conducted in the
LightCycler® Nano (Roche). The relative expression of
genes (PTEN and GAPDH) was calculated with the 2-







One day prior to the transfection, Saos and MG63 cells
were seeded onto 6 well plates (1 × 105 cells/well) and
incubated with the complete medium without antibi-
otics (2 ml/well). The transfection of hsa-miR-93 in-
hibitor (5, 10, 20, 40, 80nM) or negative control
miRNAs (Control-miR) (5, 10, 20, 40, 80nM) (Invitro-
gen) was performed using Lipofectamine 2000 reagent
(Invitrogen) in antibiotics-free OptiMEM (Invitrogen)
according to the manufacturer’s instructions. After
48 h incubation following the transfection, the cells
were harvested and processed for further analysis.Cell proliferation assay
The PTEN expression plasmid (SC119965) was obtained
from OriGene Tech. Inc (Iowa, USA). The Saos and
MG63 cells were plated in 6-well plates (1 × 105 cells per
well), and were transfected with or without anti-miR-93
inhibitor, negative control miRNA, PTEN plasmid and
Mock plasmid vector using Lipofectamine 2000. Then
the cells were incubated in antibiotic-free OptiMEM.
After 48 h of the cultivation, the cells were counted
using TC10 Automated Cell Counter (BioRad).
Western blot
Total cellular protein (15 μg) was resolved on a precast
10 % Tris–HCl Criterion 10-well gel (Biorad) at 200 V
(300 mAmp) for 30 min. The gel was wet-transferred to
a PVDF membrane for 1 h, and blocked with PBST con-
taining 5 % instant dry non-fat milk for 30 min at room
temperature. Primary antibodies (×1000) Rabbit source
(1000) against PTEN (#9552), β-Actin (#4970), Akt
(#4691), p-Akt (#4060), p21 (#2947), Bad (#9292) and
p-Bad (#9291) proteins were obtained from Cell Signal
Technology (Tokyo, Japan). Antibodies Rabbit source
against p-p21 (ab47300) was obtained from Abcam
(Tokyo, Japan). Immunocomplexes were visualized with
horseradish peroxidase-conjugated anti-rabbit immuno-
globulin G antibodies (×1000) (GE Healthcare, Tokyo,
Japan), developed the blots using ECL Prime system (GE
Healthcare) with a ChemiDoc camera (ImageQuant LAS
4000mini; GE Healthcare). The quantification of western
blot signals was performed by the densitometry with
ImageQuant TL software (GE Healthcare). All western
blot experiments were repeated at least three times.
Cell cycle analysis
For cell cycle analysis, Saos cells were stained with propi-
dium iodide using Cycletest Plus DNA Reagent Kit (BD
Biosciences) following the manufacturer’s protocol, and
the cell cycle distribution was analyzed by FACSVerse
flowcytometer (BD Biosciences). The percentages of cells
in G0⁄G1, S, and G2⁄M phases were counted and com-
pared. The experiments were carried out in triplicate.
Apoptosis assay
The changes in the expression of apoptotic proteins were
analyzed by western blot analysis using antibodies against
PAR/poly (ADP-ribose) polymerase (PARP) (#9542) and
cleaved PARP (#9541) (Cell signaling Tech, Tokyo, Japan)
as an index of apoptosis.
The quantification of cell death was determined by
fluorescence activated cell sorting (FACS) using Annexin
V-FITC apoptosis detection kit (BD Bioscience) accord-
ing to the manufacturer’s instructions. Briefly, 1 × 106
Saos cells were seeded and incubated for 24 h, then anti-
miR-93 or PTEN expression plasmid was added to the
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washed with PBS, suspended in annexin V binding buf-
fer, then added to an annexin V-FITC solution and pro-
pidium iodide (PI) for 20 min at room temperature. The
samples were analyzed by FACSVerse using FACSuite
analysis software (BD Bioscience). Adriamycin (ADM) is
commonly used for the induction of apoptosis as posi-
tive control. To verify the ability for induction of apop-
tosis, Saos cells treated with low dose ADM at 5 μg/ml
for 24 hours were used.
In vivo tumor bearing nude mice models
The experimental tumor bearing model was established
by injection of 2 x 106 cells transfected with anti-miR-93
suspended in 100 μl of normal saline into the gluteal
region of nude mice (BALB/c nu/nu, Kudo, Tosu, Japan).
Four groups were generated: (1) untreated control (n = 7);
(2) transfected with negative control-miRNA (n = 7); (3)
transfected with anti-miR-93 (n = 7); and (4) transfectedFig. 1 microRNA and cDNA array analysis in OS cell lines. a Heat map of g
down-regulated in all five OS cell lines. b Whole genome mRNA profile and e
hMSCs. The color bar represented the grades of the relative expression levels;with PTEN expression vector (n = 7). All mice were fed in
standard condition with weight monitoring and sacrificed
6 weeks after the cell inoculation. Tumor size was mea-
sured in two perpendicular dimensions parallel with the
surface and the depth of the tumor in mice using a caliper.
The primary tumor volume was estimated using the
formula V = (Length ×Width2)/2.
Immunofluorescence microscopy
To determine the effect of anti-miR-93 and PTEN ex-
pression vector on the protein level of PTEN, we also
performed immunofluorescence staining with PTEN
(CST) or p-Akt antibodies (CST). After 48 hours, the
transfected Saos cell lines were fixed with 4 % formalde-
hyde for 20 minutes, then incubated with 0.5 % Triton
X-100. A rabbit anti-Human PTEN/p-Akt antibody was
used for immunofluorescence staining. Following three
washes with PBS, the cells were incubated with a goat
anti-rabbit Alexa Fluor 594 antibody (Life Technology).enome-wide miRNA profile in five OS cell lines and hMSCs. miR-93 was
xtraction of PTEN and related genes as same pathways in OS cells and
increase was represented by red while decrease was indicated by blue
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Statistical analysis was carried out using SPSS 18.0 soft-
ware (SPSS Japan Inc, Tokyo, Japan). Two-tailed student’s
t-test was used for analysis of continuous variables. We de-
termined the differences among more than 3 groups using
a nonrepeated measures analysis of variance (ANOVA)
and Scheffe test. Results were expressed as the mean ±
standard deviation, and p < 0.01 was considered as statisti-
cally significant.
Result
Up regulation of miR-93 expression in OS cell lines
The genome-wide miRNA expression profiling using five
OS cell lines was carried out to identify miRNAs specif-
ically expressed in OS cells. The array analysis showed
that the expressions of 435 miRNAs in OS cells were
changed (fold-change >2.0) in comparison with hMSCsFig. 2 miR-93 inhibits PTEN mRNA expression in Saos cells and silencing o
at the 3′UTR site of PTEN, as aligned by Target Scan and BLAST. b Scheme
actinomycinD treatment, the miRNA expression level of miR-93 in the nega
PCR. d After actinomycinD treatment, the mRNA expression level of PTEN a
was measured by qRT-PCR. e Up-regulation of PTEN using anti- miR-93 and
PTEN protein after transfection of anti-miR-93. g Transfection of PTEN expre
quantification of PTEN protein after transfection of PTEN expression vector.(Fig. 1a). Among 435 miRNAs, 186 were significantly
upregulated, whereas 170 were significantly down regu-
lated in all tested OS cells compared with hMSCs. The
remaining 79 miRNAs were upregulated or down regu-
lated among the five OS cell lines. In OS cell lines, the
increased expression of miR-93 by 2.22 ~ 3.57 folds com-
pared with hMSCs was observed.
Down regulation of PTEN expression in OS cell lines
The cDNA array analysis demonstrated that the expres-
sions of 761 mRNAs were significantly changed between
the five OS cell lines and hMSCs (Fig. 1b). We found that
124 genes were significantly upregulated, 448 genes were
significantly down regulated, and the remaining 189 genes
were up or down regulated in the five OS cell lines com-
pared with hMSCs. The expression of PTEN was decreased
by −2.05 ~ − 9.95 fold change in five OS cell lines.f PTEN with anti-miR-93 in OS cells. a Predicted binding sites of miR-93
and sequence of the intact miR- 93 (Wt) and its mutant (Mut). (c) After
tive control-miR, miR-93 and miR-93 mutant was measured by qRT-
fter transfection of negative control-miR, miR-93 and miR-93 mutant
PTEN-expression vector in ES cells. f Densitometry quantification of
ssion vector in ES cells increases the expression of PTEN protein. h The
ANOVA was carried out to statistically analyze the results. (**) P < 0.01
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The region complementary to the miR-93 seed region was
found in the 3′-UTR of human PTEN (Fig. 2a). A consider-
able complementarity between sequences within the seed
regions of miR-93 and sequences in the 3′ untransrated re-
gion (UTR) of PTEN was predicted, using the algorithms in
BLAST and TargetScan. The results suggested that miR-93
might affect the expression of PTEN genes by binding to 3′
UTR of PTEN. We blocked de novo mRNA transcription
using actinomycin D (10 μg/ml), an inhibitor of mRNA
transcription to determine changes in miRNA or mRNA
stability. To test whether miR-93 expression affected en-
dogenous PTEN expression, we transfected the miR-93 and
miR-93 mutant oligonucleotides, as well as the negative
control-miR, into Saos cells (Fig. 2b). We observed an in-
creased miR-93 expression by 4.41 ± 0.96 fold compared
with miR-93 mutant (0.99 ± 0.71) or control-miR (1.00 ±
0.53) (p < 0.01) (Fig. 2c). And decreased PTEN expression at
the mRNA level following transfection with the miR-93-5pFig. 3 Cell proliferation assay performed to evaluate the anti-proliferation e
anti-miR-93 (a) and (b) and PTEN vector (c and d) in OS cells. Error bars rep
student t-test was employed to statistically analyze the results: (**) P < 0.01oligonucleotide 0.4 ± 0.22 compared with miR-93 mutant
(0.75 ± 0.14) or control-miR (0.81 ± 0.13) (p < 0.01) (Fig. 2d).
Up-regulation of PTEN expression by anti-93 miRNA and
PTEN expression vector
To examine the correlation between miR-93 and PTEN
in OS cells, miR-93 inhibitor anti-miR-93 was trans-
fected into Saos cells. Western blot analysis showed that
the expression levels of PTEN dramatically increased in
anti-miR-93 transfected cells compared with untreated
or negative control-miR transfected cells (Fig. 2e). The
protein expression level of PTEN in the anti-miR-93
(20nM) transfected cells was increased to 3.45 folds of
that in the control cells (p < 0.01) (Fig. 2f ). To further
confirm the effects of PTEN on the growth of OS cells,
the transfection with PTEN expression vector was car-
ried out. Although the expression level of PTEN protein
in the cells transfected with Mock vector was not signifi-
cantly affected, that in the cells transfected with PTENffect. Cell proliferation assay to evaluate the antiproliferation effect of
resent mean ± S.D. from three independent experiments. The two-tail
Fig. 4 A western blot analysis of PTEN, Akt and other factors related
to cell cycle and apoptosis. Effect of anti-miR-93 and PTEN
expression vector on PTEN protein expression and its downstream
factors in Saos cells after 48 hours of transfection
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mined by Western blot (Fig. 2g). Compared to the con-
trol cells (100 %), PTEN vector (1 μg) transfected cells
exhibited the significantly higher PTEN expression level
by 2.39 folds (p < 0.01) (Fig. 2h).
Suppression of OS cell growth by transfection of anti-93-
miR and PTEN plasmid vector
PTEN is known to play important roles in the regulation
of cell proliferation. Since the transfection of anti-miR-
93 resulted in the reduction of PTEN expression, we
next examine the effects of anti-miR-93 on the prolifera-
tion of ES cells. The cell growth of Saos (Fig. 3a) and
MG63 (Fig. 3b) was inhibited by the transfection of anti-
miR-93 as determined by cell counting in comparison
with untreated and negative control-miRNA transfected
cells at 48 h after the transfection. PTEN plasmid vector
transfected Saos (Fig. 3c) and MG63 (Fig. 3d) cells, as
same as anti-miR-93 transfected cells, showed significant
inhibition of the cell proliferation compared with the un-
treated and mock plasmid vector transfected cells.
PTEN restoration induced the expression change of Akt
To examine the correlation between PTEN and Akt, the
expression of PTEN, Akt, and their downstream factors
were investigated in Saos cells after 48 hours of transfec-
tion. Saos transfected miR-93 inhibitor and PTEN vector
showed the increase in expression of PTEN, phospho
(p)-p21 and p-Bad. Western blot analysis showed that
the expression levels of p-Akt dramatically decreased in
anti-miR-93 and PTEN vector transfected cells com-
pared with untreated, negative control oligo and Mock
vector transfected cells (Fig. 4).
Induction of cell cycle arrest at G0/G1 phase by
anti-miR-93
Since the introduction of anti-miR-93 significantly inhib-
ited cell proliferation of OS Saos cell lines, we hypo-
thesized that anti-miR-93 might reduce the cell cycle
progression and⁄or induce-apoptosis of the cells. To
monitor the cell cycle distributions, FACS analyses were
carried out using anti-miR-93 and PTEN plasmid trans-
fected cells (Fig. 5a-d). Both in anti-93-miR and PTEN
plasmid transfected cell lines, the number of the cells in
G2⁄M and G0/G1 phase was significantly lower and
higher than that in the control cells, respectively (Fig. 5e).
The data suggested that the repression of miR-93 and
restoration of PTEN might have resulted in G0⁄G1
retardation in OS cells. Then the cellular expression of
PARP and its cleaved product was assayed by immuno-
blotting in Saos cells and their transfectants (Fig. 5f ).
The cleavage of PARP protein, a marker of caspase‑
mediated apoptosis, was not observed in both anti-
miR-93 and PTEN transfectants as well as untreatedcells and negative control or mock plasmid vector trans-
fectants. Additional low dose ADM treatment could in-
duced expression of cleaved PARP in both anti-93-miR
and PTEN transfectant, which were not observed in un-
treated cells, negative control and mock plasmid vector
transfectants. (Fig. 5g). Furthermore, in flow cytometry
analysis using Annexin V-FITC/PI double staining, there
were no significantly differences in the distribution pat-
terns between untreated, negative control miRNA, anti-
miR-93 and PTEN plasmid transfected cells (Fig. 5h).
The programmed cell death was induced by low dose
ADM treatment in anti-miR-93 or PTEN plasmid vector
in Saos cells (Fig. 5i).
Inhibition of tumor growth in nude mice xenograft model
by anti-93-miR
We next investigated the efficacy of anti-miR-93 against
tumor growth in vivo. The introduction of anti-miR-93
into Saos cells resulted in the decreased growth of subcuta-
neous xenografted tumors in nude mice (Fig. 6a). Saos cells
transfected with anti-miR-93 showed statistically smaller
tumors in mice compared to untreated and negative con-
trol miRNA transfected groups (Fig. 6b.), indicating that
anti-miR-93 also inhibited the growth of OS cells in vivo.
The expression of PTEN (Fig. 6c) and p-AKT (Fig. 6e)
within the primary tumor lesion was reduced in the
anti-miR-93 and PTEN expression vector transfected
Fig. 5 Effects of anti-miR-93 and PTEN expression vectors on the cell cycle distribution in Saos. Cells were treated and analyzed by flow cytometry after
staining with PI (a-d). Histogram shows quantitative percentage of diploid cells (DNA content) in each cell cycle phase (e). Effects of anti-93-miR and
PTEN vector on induction of apoptosis in Saos. Western blot showed the expression of PARP and its cleaved form (f). Transfection of anti-93-miR and
PTEN plasmid with low dose Adriamycin showed the expression of PARP and its cleaved form Saos (g). The cells were labelled with FITC annexin V
and PI in oligo transfection (h) and oligo transfection with low dose Adriamycin (i). Each quadrants represent viable cells (Lower Left quadrant), early
apoptotic cells (Lower Right), late or secondary necrotic cells (Upper Right), and primary necrotic cells (Upper Left), respectively
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unit area was higher (p < 0.01) in the mice that anti-
miR-93 (208.3 ± 30.8 cells/mm2) and PTEN expression
vector 233.8 ± 57.9 cells/mm2) than in those that re-
ceived untreated (56.7 ± 16.7 cells/mm2) and control-
miR (101.5 ± 28.1 cells/mm2) (Fig. 6d). The number of
p-Akt positive cells per unit area was lower (p < 0.01) in
the mice that ati-miR-93 (117.6 ± 31.1 cells/mm2) and
PTEN expression vector (68.8 ± 25.1 cells/mm2) than in
those that received untreated (234 ± 42.2 cells/mm2) and
control-miR (206.2 ± 57 cells/mm2). (Fig. 6f ).
Discussion
miRNAs are small (19–25 nucleotides), noncoding RNAs
capable of modulating the expression of their cognate tar-
get genes by binding to the 3′-UTR of mRNAs, causing
either translational inhibition or mRNA cleavage [3, 4].
They are expressed in a tissue-specific manner and play
an important role in cell proliferation, apoptosis, and dif-
ferentiation. It has been shown that miRNAs play crucialroles in the regulation of diverse biological processes, such
as development, inflammation, and tumorigenesis [14].
miRNAs are frequently dysregulated in human cancers
and can act either as potent oncogenes or as tumor sup-
pressors [15, 16]. To identify important miRNA–mRNA
relationships in OS, we performed genome-wide miRNA
and cDNA arrays on the same OS cells.
In the present study, our miRNA array results demon-
strated that the expression of miR-93 was up-regulated in
all five OS cell lines. miR-93 overexpression plays an im-
portant role in promoting lung cancer cell growth, angio-
genesis, and metastasis, while its inhibition suppresses cell
proliferation, migration, and colony formation [17, 18].
Furthermore, additional in vitro and in vivo experiments
have demonstrated the critical role of miR-93 in regulating
cancer cell growth and promotion of tumor progression
[19, 20]. The function of miR-93 has been reported to be
important in the ecology of other types of cancer via tar-
geting of PTEN [5, 20, 21]. However, the biological role of
miR-93 including the relationship to PTEN in OS cells has
Fig. 6 Anti-miR-93 and PTEN vector suppressed in vivo tumor growth. Four groups were; (1) untreated (n = 7); (2) transfected with of negative control-
miRs (n = 7); (3) transfected with anti-miR-93 (n = 7); and (4) transfected with PTEN expression vector (n = 7). Tumor volumes were measured at the
time points indicated after the tumor cell inoculation. (**) P < 0.01. Immunofluorescence of PTEN (c) and p-Akt (f) following transfection of anti-miR-93
and PTEN vector into tumor cells. The number of PTEN (d) and p-Akt (f) positive cells per unit area in the tumor lesion
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expression was consistently up-regulated in OS cell lines,
we employed genome-wide mRNA profiling by cDNA
array to identify possible targets of miR-93 in OS cells.
Data from cDNA arrays showed that PTEN mRNA
expression was invariably diminished in OS cell lines, in
comparison to hMSCs. Furthermore, sequence analysis
suggested a possible association of miR-93 with the
3′-UTR of PTEN. PTEN is a plasma membrane lipid
phosphatase and tumor suppressor that dephosphorylates
phosphatidylinositol 3,4,5-trisphosphate to the bipho-
sphate phosphatidylinositol 4,5-bisphosphate, thereby inhi-
biting the phosphorylation of Akt [22, 23]. Studies of the
Akt pathway have shown that a chromosome 10 deletion
of phosphoinositide 3-kinase (PI3K)/PTEN can facilitate
tumorigenesis [24, 25]. Our data, generated using OS cells,
is consistent with that of previous studies showing that
down-regulation of PTEN may contribute to malignancy.
Although miR-93 may influence the expression of
many genes, we focused on PTEN as its target in OScells. Several genes have been reported to be targets of
miR-93, including RhoC, CCNG2, RBL2, NRF2, and
DAB2 [17, 19, 26–28]. Our cDNA array analysis demon-
strated that PTEN was the only miR-93 target gene
whose expression was uniformly up-regulated in all five
OS cell lines. The expression of the other candidate
genes differed between these lines. An analysis using
several algorithms, such as BLAST and TargetScan, fur-
ther recommended PTEN as a putative target of miR-93.
Therefore, we considered the possibility that miR-93
might affect anticarcinogenic mechanisms by targeting
PTEN in OS cells. It is possible that miR-93 may down-
regulate PTEN expression via an indirect pathway. In
order to examine whether miR-93 really inhibits PTEN
mRNA function, we stopped new transcription with acti-
nomycin D and then introduced miR-93 and a mutant
with a changed seed region. The miR-93 mutant did not
result in any changes, whereas the miR-93 introduction
group demonstrated a reduction in PTEN mRNA; there-
fore, miR-93 sequence can indeed be anticipated to
Kawano et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:76 Page 10 of 11directly inhibit PTEN mRNA function. Therefore, miR-
93 may have affected PTEN mRNA through direct inter-
action, at least in part.
We next examined the function of miR-93 in regulat-
ing its potential target gene, PTEN, and in modifying the
biological characteristics of OS cells. The over-expression
of miR-93 resulted in the suppression of PTEN protein
levels, indicating that miR-93 might function as an onco-
gene in OS cells. Several studies have demonstrated that
PTEN, a cell cycle and proliferation regulator, is the direct
target of miR-93 in breast cancer [5, 20, 29]. Our results
suggest for the first time that the same regulatory mech-
anism may operate in OS cells. The expression of miR-93
has been identified in various types of cancer, suggesting
an oncogenic role [6, 30, 31]. For instance, its overexpres-
sion in breast cancer has been correlated with prolifera-
tion and tumor progression [8].
Our data show that miR-93 promoted the proliferation
of OS cells via induction of cell cycle retardation at the
G1/G0 phase. This observation is consistent with a
previous report demonstrating that overexpression of
miR-93 promotes glioma cell proliferation and cell cycle
progression [30, 31]. It has been shown that PTEN plays
important roles in regulating G1/S transition and cellu-
lar transformation, and that restoring PTEN expression
results in G1-phase cell cycle arrest [32]. Thus, we can
assume that up-regulation of miR-93 might affect OS
cell cycle progression via control of PTEN expression. It
is noteworthy that up-regulation of PTEN by transfec-
tion with vectors encoding anti-miR-93 or PTEN itself
induced apoptosis of OS cells, indicating that the repres-
sion of OS cell growth following restoration of PTEN
expression came about by apoptosis, as well as by cell
cycle retardation.
Given that PTEN acts as a major negative regulator of
the PI3K/Akt signaling pathway, its inhibition by miR-93
might play an important role in the proliferation of other
cell types [20]. Akt represses p21 and Bax, promoting
cell proliferation and preventing apoptosis [33, 34].
Thus, down-regulation of Akt by PTEN in ES cells may
increase p21 and Bax expression, leading to cell cycle
retardation and apoptosis of OS cells.
Furthermore, the repression of miR-93 resulted in in-
hibition of OS tumor growth in vivo. Consistent with
data from our in vitro experiments, the xenograft model
of OS also indicated that this mechanism operates via
restoration of PTEN expression.
Conclusion
In summary, the present study demonstrates for the first
time an inverse correlation between miR-93 and PTEN
in OS cells. In addition, we have provided evidence that
the expression of miR-93 in OS cells is significantly in-
creased, and that this miRNA plays important roles inOS cell proliferation and tumorigenesis by targeting
PTEN both in vitro and in vivo. The silencing of PTEN
has been observed in several human cancers, in which it
potently promotes cell growth and proliferation [35].
Our data suggest that PTEN expression constitutes one
of the crucial factors determining tumor proliferation in
ES, as in other malignant tumors. Although future con-
firmation of the data presented in the current study using
clinical OS samples is necessary, the novel information
provided here regarding the link between miR-93 and
PTEN in OS cells will be beneficial in better understand-
ing ES oncogenesis, and may suggest certain therapeutic
strategies for clinical application.
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